Pembrolizumab Drug Substance Suppliers & Bulk Manufacturers

Available Forms: Drug substance (bulk)

Available Strengths: Supplied to an in-house or pharmacopoeial specification

Reference Brands: Keytruda

Category: Active Pharmaceutical Ingredient

Pembrolizumab drug substance is the anti-PD-1 monoclonal antibody behind many cancer immunotherapy regimens. It is sought by biosimilar developers and licensed biologics partners.

Product Description:

Pembrolizumab is a humanised IgG4 kappa monoclonal antibody that binds the PD-1 receptor on T cells and releases a brake on the immune response against tumours. It is approved across a wide range of cancers, among them melanoma, non-small cell lung cancer, head and neck, urothelial, cervical, gastric, oesophageal, endometrial and triple-negative breast cancer, and MSI-H or mismatch repair-deficient tumours, each under the specific conditions of the label (reference brand: Keytruda).

Specification at a glance

Regulatory files and timing

Biologic drug substance is usually supplied in bulk under a long-term supply agreement, or licensed together with the dossier, rather than bought as a one-off API order. Buyers typically ask for the drug substance comparability package, cell bank and process documentation, and the supplier's GMP status.

Generic or biosimilar entry. United States: Patent expiry; entry not confirmed (2028). European Union: Entry expected (2031 (including SPC)). Sources and updates are on our generic and biosimilar entry tracker.

Handling and quality points

Pembrolizumab drug substance has to stay within a validated temperature range, refrigerated or frozen depending on the process, so ask for shipping validation and freeze-thaw data. Aggregates, charge variants and glycan profile need close control, and a biosimilar programme stands or falls on detailed comparability with the reference product. Check patent and regulatory exclusivity in each target market before planning commercial supply.

Send an API enquiry All specialty APIs

Brand names are trademarks of their respective owners and identify the reference medicine only. Information is general and was checked in October 2026; confirm specifications and filings with the supplier before purchase.